Choose the brand aligned with your industry so we can best serve your needs.
For researchers, scientists, and technical professionals: Your one-stop shop for the complete range of laboratory, production, and safety products and services.
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
Rigosertib sodium salt (CAS 1225497-78-8) is a selective inhibitor targeting Polo-like kinase 1 (PLK1) with reported IC50 approximately 9 nM The compound notably decreases proliferation of cancer cell lines demonstrating nanomolar IC50 values in HeLa (115 nM) and C33A (45 nM) cells whereas normal cells (e g BJ and Ect1/E6E7) remain largely unaffected At concentrations exceeding 0 5 M rigosertib robustly induces G2/M phase arrest in cancer cells without significant cell cycle disruption at lower doses Additionally in vivo studies suggest its potential as a radiosensitizer in cervical carcinoma research
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
Rigosertib sodium salt (CAS 1225497-78-8) is a selective inhibitor targeting Polo-like kinase 1 (PLK1) with reported IC50 approximately 9 nM The compound notably decreases proliferation of cancer cell lines demonstrating nanomolar IC50 values in HeLa (115 nM) and C33A (45 nM) cells whereas normal cells (e g BJ and Ect1/E6E7) remain largely unaffected At concentrations exceeding 0 5 M rigosertib robustly induces G2/M phase arrest in cancer cells without significant cell cycle disruption at lower doses Additionally in vivo studies suggest its potential as a radiosensitizer in cervical carcinoma research
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More
Small and Specialty Supplier Partner Small and/or specialty supplier based on Federal laws and SBA requirements. Learn More
Rigosertib sodium salt (CAS 1225497-78-8) is a selective inhibitor targeting Polo-like kinase 1 (PLK1) with reported IC50 approximately 9 nM The compound notably decreases proliferation of cancer cell lines demonstrating nanomolar IC50 values in HeLa (115 nM) and C33A (45 nM) cells whereas normal cells (e g BJ and Ect1/E6E7) remain largely unaffected At concentrations exceeding 0 5 M rigosertib robustly induces G2/M phase arrest in cancer cells without significant cell cycle disruption at lower doses Additionally in vivo studies suggest its potential as a radiosensitizer in cervical carcinoma research
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More